Evidence mapPaperPMID 37991502Full record

ArticleBioconjugate chemistry2023

mCherry on Top: A Positive Read-Out Cellular Platform for Screening DMD Exon Skipping Xenopeptide-PMO Conjugates.

Anna-Lina Lessl, Jana Pöhmerer, Yi Lin, Ulrich Wilk, Miriam Höhn, Elisa Hörterer, Ernst Wagner, Ulrich Lächelt

Open access · hybridAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Anna-Lina LesslPharmaceutical Biotechnology, Department of Pharmacy, LMU Munich, Butenandtstrasse 5-13, 81377 Munich, Germany.
Jana PöhmererPharmaceutical Biotechnology, Department of Pharmacy, LMU Munich, Butenandtstrasse 5-13, 81377 Munich, Germany.
Yi LinPharmaceutical Biotechnology, Department of Pharmacy, LMU Munich, Butenandtstrasse 5-13, 81377 Munich, Germany.ORCID 0000-0002-8916-7901
Ulrich WilkPharmaceutical Biotechnology, Department of Pharmacy, LMU Munich, Butenandtstrasse 5-13, 81377 Munich, Germany.
Miriam HöhnPharmaceutical Biotechnology, Department of Pharmacy, LMU Munich, Butenandtstrasse 5-13, 81377 Munich, Germany.
Elisa HörtererPharmaceutical Biotechnology, Department of Pharmacy, LMU Munich, Butenandtstrasse 5-13, 81377 Munich, Germany.
Ernst WagnerPharmaceutical Biotechnology, Department of Pharmacy, LMU Munich, Butenandtstrasse 5-13, 81377 Munich, Germany.ORCID 0000-0001-8413-0934
Ulrich LächeltPharmaceutical Biotechnology, Department of Pharmacy, LMU Munich, Butenandtstrasse 5-13, 81377 Munich, Germany.ORCID 0000-0002-4996-7592
Ludwig-Maximilians-Universität München · DECenter for NanoScience · DEUniversity of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphorodiamidate morpholino oligomers (PMOs) are a special type of antisense oligonucleotides (ASOs) that can be used as therapeutic modulators of pre-mRNA splicing. Application of nucleic-acid-based therapeutics generally requires suitable delivery systems to enable efficient transport to intended tissues and intracellular targets. To identify potent formulations of PMOs, we established a new

Indexed as

DystrophinMuscular Dystrophy, DuchenneAnimalsExonsHeLa CellsHumansMiceMice, Inbred mdxMorpholinosDystrophinMorpholinos

Identifiers

PMID37991502
PMCPMC10739591
OpenAlexW4388899165

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.